Clinical Trial Update: A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. [Phase 3]

View source ↗

Summary

A Phase 3 extension study (NEPTUNUS) evaluates long-term safety and efficacy of ianalumab in patients with Sjögren's syndrome; the trial is active but not curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjogrens Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING